Lee Kevin M C, Achuthan Adrian A, Hamilton John A
Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, 3050, Australia.
Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne and Western Health, Melbourne, VIC, Australia.
Immunotargets Ther. 2020 Oct 29;9:225-240. doi: 10.2147/ITT.S262566. eCollection 2020.
The cytokine, granulocyte macrophage-colony stimulating factor (GM-CSF), was firstly identified as being able to induce in vitro the proliferation and differentiation of bone marrow progenitors into granulocytes and macrophages. Much preclinical data have indicated that GM-CSF has a wide range of functions across different tissues in its action on myeloid cells, and GM-CSF deletion/depletion approaches indicate its potential as an important therapeutic target in several inflammatory and autoimmune disorders, for example, rheumatoid arthritis. In this review, we discuss briefly the biology of GM-CSF, raise some current issues and questions pertaining to this biology, summarize the results from preclinical models of a range of inflammatory and autoimmune disorders and list the latest clinical trials evaluating GM-CSF blockade in such disorders.
细胞因子粒细胞巨噬细胞集落刺激因子(GM-CSF)最初被鉴定为能够在体外诱导骨髓祖细胞增殖并分化为粒细胞和巨噬细胞。许多临床前数据表明,GM-CSF在作用于髓系细胞时,在不同组织中具有广泛的功能,并且GM-CSF缺失/耗竭方法表明其在几种炎症和自身免疫性疾病(例如类风湿性关节炎)中作为重要治疗靶点的潜力。在本综述中,我们简要讨论GM-CSF的生物学特性,提出一些与该生物学特性相关的当前问题,总结一系列炎症和自身免疫性疾病临床前模型的结果,并列出评估GM-CSF阻断在此类疾病中的最新临床试验。